Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 study of MK-7684A in relapsed or refractory hematologic malignancies
MOH_2021-10-17_010145Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Aug 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vibostolimab + pembrolizumab in hematopoietic malignancies, classical Hodgkin lymphoma (cHL), primary mediastinal large B-cell lymphoma (PMBCL) and 4 more, sponsored by Merck & Co. Started Aug 2021; status: recruiting.
02
Drugs
vibostolimab + pembrolizumab
03
Conditions
hematopoietic malignanciesclassical Hodgkin lymphoma (cHL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on MOH_2021-10-17_010145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-10-17_010145.